文献速递瓣膜外科

老年患者机器人二尖瓣修复术:胸外科医师学会数据库分析

Robotic Mitral Valve Repair in Older Individuals: An Analysis of The Society of Thoracic Surgeons Database.
PubMed 文献 · Ann Thorac Surg · 2018-06-30

该研究基于胸外科医师学会成人心脏外科数据库与医疗保险理赔数据,纳入2011至2014年65岁及以上接受二尖瓣修复术的患者,将机器人二尖瓣修复术(rMVr)与胸骨正中切开二尖瓣修复术(sMVr)进行倾向性匹配。匹配后各503例,rMVr组术后房颤和输血更少、重症监护室和住院时间更短,但体外循环和主动脉阻断时间更长;两组3年死亡率、心力衰竭再入院率和二尖瓣再干预率无显著差异。

要点

  • 匹配后rMVr组与sMVr组各503例,rMVr来自65个中心,sMVr来自251个中心。
  • rMVr组体外循环和主动脉阻断时间均长于sMVr组,差异有统计学意义。
  • rMVr组重症监护室时间、住院时间、输血和房颤发生率均低于sMVr组。

核心结论

  • 在老年患者中,rMVr与较少的房颤、较少的输血需求以及较短的重症监护室和住院时间相关,3年死亡率、心力衰竭再入院率或二尖瓣再干预率无显著差异。
  • 在老年患者中,rMVr带来短期优势,且不损害中期结局。

研究设计与样本

  • 研究基于胸外科医师学会成人心脏外科数据库与医疗保险理赔数据,纳入2011至2014年65岁及以上接受二尖瓣修复术的患者。
  • 将接受rMVr的患者与接受sMVr的患者进行倾向性匹配,匹配后rMVr组503例来自65个中心,sMVr组503例来自251个中心。
  • 采用Cox模型计算3年死亡率、心力衰竭再入院率和二尖瓣再干预率,并在适当情况下校正竞争风险。

主要发现

  • rMVr组体外循环时间125分钟 vs sMVr组102分钟(p < 0.0001),主动脉阻断时间85分钟 vs 75分钟(p < 0.0001)。
  • rMVr组重症监护室时间27小时 vs sMVr组47小时(p < 0.0001),住院时间5天 vs 6天(p < 0.0001)。
  • rMVr组输血21% vs sMVr组35%(p < 0.0001),房颤28% vs 40%(p < 0.0001)。
  • 3年死亡率风险比1.21(95%CI 0.68至2.16,p = 0.52),心力衰竭再入院风险比1.42(95%CI 0.80至2.52,p = 0.10),二尖瓣再干预风险比0.42(95%CI 0.15至1.18,p = 0.22),两组间均无显著差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: National outcomes of robotic mitral valve repair (rMVr) compared with sternotomy (sMVr) in older patients are currently unknown. METHODS: From 2011 to 2014, all patients aged 65 years and older undergoing MVr in The Society of Thoracic Surgeons Adult Cardiac Surgery Database linked to Medicare claims data were identified. Patients who underwent rMVr were propensity matched to patients who underwent sMVr. Standard differences and falsification outcome of baseline characteristics were tested to ensure a balanced match. Cox models were used to calculate 3-year mortality, heart failure readmission, and mitral valve reintervention, adjusting for competing risks where appropriate. RESULTS: After matching, 503 rMVr patients from 65 centers and 503 sMVr from 251 centers were included. There were no significant differences in comorbidities or falsification outcome. Cardiopulmonary bypass and cross-clamp times were longer with rMVr versus sMVr at 125 versus 102 minutes (p < 0.0001) and 85 versus 75 minutes (p < 0.0001), respectively. The rMVr patients had shorter intensive care unit (27 vs 47 hours, p < 0.0001) and hospital stay (5 vs 6 days, p < 0.0001), less frequent transfusion (21% vs 35%, p < 0.0001), and less atrial fibrillation (28% vs 40%, p < 0.0001). Three-year mortality (hazard ratio, 1.21; 95% confidence interval, 0.68 to 2.16; p = 0.52), heart failure readmission (hazard ratio, 1.42; 95% confidence interval, 0.80 to 2.52, p = 0.10), and mitral valve reintervention (hazard ratio, 0.42; 95% confidence interval, 0.15 to 1.18; p = 0.22) did not differ between the groups. CONCLUSIONS: The rMVr procedure was associated with less atrial fibrillation, less frequent transfusion requirement, and shorter intensive care unit and hospital stay, without a significant difference in 3-year mortality, heart failure readmission, or mitral valve reintervention. In older patients, rMVr confers short-term advantages without a detriment to midterm outcomes.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Wang A, Brennan JM, Zhang S, et al. Robotic Mitral Valve Repair in Older Individuals: An Analysis of The Society of Thoracic Surgeons Database. Ann Thorac Surg. 2018. PMID: 29966592. doi:10.1016/j.athoracsur.2018.05.074

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。